Pediatrix Medical Group, Inc. (NYSE:MD) Receives $16.25 Average PT from Brokerages

Pediatrix Medical Group, Inc. (NYSE:MD - Get Free Report) has earned a consensus recommendation of "Hold" from the six analysts that are covering the company, Marketbeat reports. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $17.08.

A number of analysts have recently weighed in on MD shares. Macquarie started coverage on shares of Pediatrix Medical Group in a research note on Monday, December 16th. They issued an "outperform" rating and a $18.00 price target for the company. Jefferies Financial Group upped their price target on shares of Pediatrix Medical Group from $14.00 to $18.00 and gave the stock a "buy" rating in a research note on Tuesday, November 5th. Mizuho upped their price target on shares of Pediatrix Medical Group from $13.00 to $15.00 and gave the stock a "neutral" rating in a research note on Tuesday, November 19th. UBS Group upped their price target on shares of Pediatrix Medical Group from $16.50 to $18.50 and gave the stock a "neutral" rating in a research note on Friday. Finally, Truist Financial upped their price target on shares of Pediatrix Medical Group from $15.00 to $18.00 and gave the stock a "hold" rating in a research note on Friday.

Pediatrix Medical Group Stock Down 9.6 %

Shares of MD traded down $1.66 during midday trading on Wednesday, hitting $15.57. The company had a trading volume of 1,331,733 shares, compared to its average volume of 533,334. The company's 50 day moving average price is $13.89 and its 200 day moving average price is $12.99. The stock has a market cap of $1.34 billion, a price-to-earnings ratio of -12.97, a PEG ratio of 1.74 and a beta of 1.57. Pediatrix Medical Group has a 52 week low of $6.62 and a 52 week high of $17.67. The company has a quick ratio of 1.42, a current ratio of 1.60 and a debt-to-equity ratio of 0.81.

Pediatrix Medical Group (NYSE:MD - Get Free Report) last posted its quarterly earnings results on Thursday, February 20th. The company reported $0.49 EPS for the quarter, beating the consensus estimate of $0.37 by $0.12. The business had revenue of $502.36 million during the quarter, compared to analyst estimates of $486.22 million. Pediatrix Medical Group had a negative net margin of 4.92% and a positive return on equity of 15.47%. On average, equities research analysts predict that Pediatrix Medical Group will post 1.38 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Mackenzie Financial Corp acquired a new position in Pediatrix Medical Group in the 4th quarter valued at approximately $276,000. PharVision Advisers LLC acquired a new position in Pediatrix Medical Group in the 4th quarter valued at approximately $245,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Pediatrix Medical Group by 7.8% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 256,335 shares of the company's stock worth $3,363,000 after acquiring an additional 18,627 shares in the last quarter. Voloridge Investment Management LLC bought a new stake in Pediatrix Medical Group in the fourth quarter worth approximately $396,000. Finally, Squarepoint Ops LLC bought a new stake in Pediatrix Medical Group in the fourth quarter worth approximately $132,000. Institutional investors and hedge funds own 97.71% of the company's stock.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.